

KOT-0085

REMARKS

Claims 1-51 were pending in the application. Claims 1, 8, 15, 49, and 50 have been amended and Claims 36-42 have been canceled, leaving Claims 1-35 and 43-51 for further consideration in the present amendment. Applicants appreciate the indication that Claims 22-25 stand allowed.

Claims 1 and 8 have been amended to overcome the rejection under 35 USC §112. Claim 15 has been amended to delete the compound of Formula H1 and to delete a substituted or unsubstituted aryl group from the substituents represented by R_{h5} and R_{h6} of Formula H4. Claims 49 and 50 have been amended to provide greater clarification. Support for these claim amendments can be found in the originally filed claims. No new matter has been introduced by these amendments.

Reconsideration and allowance of the claims are respectfully requested in view of the above amendments and the following remarks.

Claim Rejections Under 35 USC §112

Claims 1-14, and 45 stand rejected under 35 USC 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The rejection of Claims 1-14 has been rendered moot in view of the amendments thereto.

Regarding Claim 45, it is submitted that Claim 45 is definite and is in independent form. The hole transporting material recited in Claim 45 is different from the electron transporting material recited in Claim 43. The hole transporting material transports holes having a positive charge. In contrast, the electron transporting material transports electrons having a negative charge. One of skill in the art would readily appreciate and recognize these differences. In view of the above, one of skill in the art would consider Claim 45 to be definite and in independent form. Withdrawal of the rejection is hereby requested.

KOT-0085

KOT-0085


Claim Rejections Under 35 U.S.C. § 102(e)

Claims 1-7, 15-21 and 36-51 stand rejected under 35 U.S.C. § 102(e), as allegedly anticipated by US Patent Publication No. 2003/0205696 to Thoms et al. (hereinafter Thoms). Applicants respectfully traverse this rejection.

Thoms does not anticipate amended independent Claims 1 and 15. Applicants have carefully studied Thoms and can find no disclosure of compounds that anticipate any of the compounds represented by these independent claims. Accordingly, the rejection is improper and is requested to be withdrawn. In the event the Examiner maintains the rejection, the Examiner is requested to specifically identify the relevant portions in the specification of Thoms that purportedly anticipates the compounds represented in Claims 1 and 15. Given that Claims 2-7 and 16-21 depend from one of these claims, these claims are not anticipated by Thoms as well.


Regarding the rejection of Claims 36-51, it is noted that Claims 36-42 have been canceled. With regard to Claims 43-51, the Examiner comments that the following host material reads on the compounds identified in Applicants' claims.

Thoms' host material:



KOT-0085

In Applicants' Claims 43-51, Formula A is represented below:



wherein R_1 , R_2 and R_3 independently represent a substituted or unsubstituted alkyl group or a substituted or unsubstituted cycloalkyl group; n_1 represents an integer of from 0 to 5; and n_2 and n_3 independently represent an integer of from 0 to 4, provided that R_1 and R_2 , R_1 and R_3 , or R_2 and R_3 , each may combine with each other to form a ring.

The Thoms material does not anticipate Formula A above. In Thoms, the host material stipulates that at least two of the R groups are represented by carbazole or substituted carbazole units (see paragraph [0061]-[0062]). Thoms fails to disclose what the remaining groups will be other than at least two of the R groups are carbazole or substituted carbazole units. Because of this, there is insufficient disclosure for one skilled in the art to determine whether or not the Thoms material reads on the compounds represented by Applicants' Formula A. As such, Thoms fails to anticipate these claims.

Moreover, with regard to the disclosure provided in Thoms at paragraph [0029], the R_2 - R_7 groups are disclosed as being hole transporting carbazole or arylamine groups. For reasons discussed above, these compounds do not anticipate the compounds of Formula A provided in Claims 43-51.

In view of the foregoing, the rejections are improper and should be withdrawn for at least these reasons.

KOT-0085

KOT-0085


Provisional Double Patenting Rejection

Filed concurrently herewith is a Provisional Terminal disclaimer. Accordingly, the rejection is requested to be withdrawn.

It is believed that the foregoing amendments and remarks fully comply with the Office Action and that the claims herein should now be allowable to Applicants. Accordingly, reconsideration and allowance are requested.

If there are any additional charges with respect to this Amendment or otherwise, please charge them to Deposit Account No. 06-1130.

Respectfully submitted,

By 
Peter R. Hagerty
Registration No. 42,618

Date: February 15, 2006

CANTOR COLBURN LLP
1170 Peachtree Street, Suite 750
Atlanta, GA 30309
Telephone (404) 607-9991
Facsimile (404) 607-9981
Customer No.: 23413

KOT-0085